NeoGenomics, Inc.
NeoGenomics, Inc. Fundamental Analysis
NeoGenomics, Inc. (NEO) shows moderate financial fundamentals with a PE ratio of -1.97, profit margin of -14.85%, and ROE of -12.64%. The company generates $0.7B in annual revenue with strong year-over-year growth of 11.65%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 11.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze NEO's fundamental strength across five key dimensions:
Efficiency Score
WeakNEO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentNEO trades at attractive valuation levels.
Growth Score
ExcellentNEO delivers strong and consistent growth momentum.
Financial Health Score
ExcellentNEO maintains a strong and stable balance sheet.
Profitability Score
WeakNEO struggles to sustain strong margins.
Key Financial Metrics
Is NEO Expensive or Cheap?
P/E Ratio
NEO trades at -1.97 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NEO's PEG of 0.06 indicates potential undervaluation.
Price to Book
The market values NeoGenomics, Inc. at 0.25 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 2.52 times EBITDA. This is generally considered low.
How Well Does NEO Make Money?
Net Profit Margin
For every $100 in sales, NeoGenomics, Inc. keeps $-14.85 as profit after all expenses.
Operating Margin
Core operations generate -15.62 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-12.64 in profit for every $100 of shareholder equity.
ROA
NeoGenomics, Inc. generates $-7.94 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
NeoGenomics, Inc. generates limited operating cash flow of $5.28M, signaling weaker underlying cash strength.
Free Cash Flow
NeoGenomics, Inc. generates weak or negative free cash flow of $-21.98M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.85 in free cash annually.
FCF Yield
NEO converts -10.10% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-1.97
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.25
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.30
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.56
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.26
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.13
vs 25 benchmark
ROA
Return on assets percentage
-0.08
vs 25 benchmark
ROCE
Return on capital employed
-0.09
vs 25 benchmark
How NEO Stacks Against Its Sector Peers
| Metric | NEO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -1.97 | 28.81 | Better (Cheaper) |
| ROE | -12.64% | 643.00% | Weak |
| Net Margin | -14.85% | -44312.00% (disorted) | Weak |
| Debt/Equity | 0.56 | 0.36 | Weak (High Leverage) |
| Current Ratio | 4.26 | 4.50 | Strong Liquidity |
| ROA | -7.94% | -17799.00% (disorted) | Weak |
NEO outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews NeoGenomics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
28.17%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-880.02%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-76.16%
Industry Style: Defensive, Growth, Innovation
Declining